To enhance the therapeutic effect of TG4010, i.e., MVA-MUC1-IL-2 cancer vaccine, we have tested the efficacy of tumor irradiation for the treatment of Renca murine RCC cells transfected with MUC1. Here, IL2 is linked to neoplasm.